Extract from the provided pathology report the following data points, seperated by semi-colons: summary cancer stage; histologic grade; ICD-10 code; ICD-O-3 code; pathologic N stage; pathologic T stage; whether the sample is of the primary tumor; the orgran of origin of the sample; and the cancer type.

Pathology report:
PATIENT HISTORY: PRE-OP DIAGNOSIS: Right renal carcinoma. POST-OP DIAGNOSIS: Not given. PROCEDURE: Not given. ADDENDA: Addendum. SPECIAL PROCEDURE REPORT. MOLECULAR ANATOMIC PATHOLOGY FLUORESCENCE IN SITU HYBRIDIZATION ANALYSIS. Comment: Molecular fluorescence in situ hybridization (FISH) analysis demonstrates presence of trisomy of chromosomes 7 and 17. in both the papillary as well as the clear cell areas of this morphologically complex renal cell carcinoma. In addition, the. papillary areas also show foci with tetrasomy of chromosome 17. This molecular phenotype is most consistent with a papillary renal cell carcinoma. Specimen type: Renal tumor. Centromere. 1. 2. 3. 4+. copy #. CEPI. Papillary Area. CEP7. 18(26.1%). 51(73.9%). CEPI7. 8(12.7%). 11(17.5%). 33(52.4%). 11(17.4%). CEPI. Clear Cell Area. CEP7. 20(33.3%). 40(66.7%). CEP17. 6(8.5%). 16(22.5%). 49(69.0%). Interpretation guidelines: Chromosomal losses are considered significant if present in greater than 30% of cells. The loss is indeterminate if present in 20-. 30% of cases. The loss is considered artifactual if seen in less than 20% of cases. Chromosomal gains are considered significant if present in greater than 20% of cells. The gain is considered artifactual if seen in. less than 20% of cases. Probes used: CEP1 (1p11.1q11.1), CEP7 (7p11.1q11.1), CEP17 (17p11.1q11.1). At least 25 cells are analyzed. The signal distribution for targeted foci of renal carcinoma is recorded. If the test results are. consistent with the clinical findings, and/or diagnostic, a consultation between pathologist and treating physician is warranted. This test was developed and its performance characteristics determined by the University of Pittsburgh, Department of Pathology. as required by the. regulations. FINAL DIAGNOSIS: RIGHT KIDNEY, NEPHRECTOMY -. A. RENAL CELL CARCINOMA (3.4 CM), FURHMAN NUCLEAR GRADE 3 / 4. B. THE TUMOR SHOWS BOTH PAPILLARY AND CLEAR CELL FEATURES (see comment). c. THE RENAL CELL CARCINOMA IS CONFINED WITHIN THE CAPSULE OF THE KIDNEY. D. THE MARGINS OF RESECTION ARE FREE OF TUMOR. E. THE URETERAL AND VASCULAR MARGINS OF RESECTION ARE UNREMARKABLE. F. NO EVIDENCE OF ANGIOLYMPHATIC INVASION SEEN. G. THE TUMOR SHOWS PROMINENT NECROSIS. H. THE SURROUNDING NON-NEOPLASTIC KIDNEY IS ESSENTIALLY UNREMARKABLE (see comment). I. TNM STAGE: T1a, Nx, Mx. COMMENT: The renal cell carcinoma shows prominent necrosis. In addition, the tumor has a mixed morphology with papiliary and. clear cell features. The exact charecterization of this lesion will be performed after molecular testing has been. accomplished. The results of the molecular tests, as well as their interpretation, will be reported in an addendum. The non-neoplastic renal parenchyma distant from the tumor is unremarkable. However, the peritumoral renal. parenchyma shows prominent glomerular sclerosis and focal areas of interstitial inflammation. Clinical and serologic. correlation is suggested.

Extracted data:
Summary Stage: Stage I
Histologic Grade: G3
ICD-10 Code: C64.9
ICD-O-3 Code: 8310/3
Pathologic N Stage: pN0
Pathologic T Stage: pT1a
Primary Tumor: Yes
Organ of origin: Kidney
Cancer Type: Kidney Clear Cell Renal Carcinoma